Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep;10(9):e689.
doi: 10.1002/iid3.689.

Anxiety and depression prevalence and their risk factors in lupus nephritis patients: A case-control study

Ying Hu  1 , Ge Zhan  2
Affiliations

Anxiety and depression prevalence and their risk factors in lupus nephritis patients: A case-control study

Ying Hu et al. Immun Inflamm Dis. 2022 Sep.

Abstract

Introduction: Anxiety and depression exhibit a high prevalence in systemic lupus erythematosus (SLE) patients, while this issue is seldom explored in lupus nephritis (LN). Hence, the current study aimed to investigate the prevalence of anxiety and depression, and the risk factors for these mental disorders in LN patients.

Methods: Fifty LN patients, 50 non-LN SLE patients, and 50 health control (HCs) were enrolled. The Hospital Anxiety and Depression Scale (HADS) for anxiety (HADS-A) score and HADS for depression (HADS-D) score were evaluated.

Results: HADS-A score was highest in LN patients (median 7.0, interquartile range [IQR]: 6.0-10.0), followed by non-LN SLE patients (median 6.0, IQR: 5.0-8.0), and lowest in HCs (median 5.0, IQR: 3.0-7.0) (p < .001). Besides, the anxiety rate was most frequent in LN patients (38.0%), followed by non-LN SLE patients (28.0%), least common in HCs (12.0%) (p = .011). HADS-D score was highest in LN patients (median 7.5, IQR: 6.0-11.0), followed by non-LN SLE patients (median 6.0, IQR: 5.0-8.3), and lowest in HCs (median 4.0, IQR: 2.0-6.3) (p < .001). Similarly, the depression rate was most prevalent in LN patients (50.0%), subsequently the non-LN SLE patients (30.0%), and rarest in HCs (10.0%) (p < .001). Furthermore, in LN patients, age (p = .009), LN activity index (p = .020), alopecia (p = .023), 24 h proteinuria (p = .044), and C-reactive protein (p = .049) were independently correlated with higher anxiety risk; meanwhile, age (p = .001) and LN activity index (p = .009) were independently correlated with higher depression risk.

Conclusion: Anxiety and depression are highly prevalent, which link to aging, alopecia, inflammation, and severe renal involvement in LN patients.

Keywords: anxiety; depression; lupus nephritis; prevalence; risk factors.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Comparison of anxiety status among HCs, non‐LN SLE, and LN patients. Comparison of HADS‐A score (A) and anxiety rate (B) among HCs, non‐LN SLE, and LN patients. HADS, Hospital Anxiety and Depression Scale; HCs, health controls; LN, lupus nephritis; SLE, systemic lupus erythematosus disease
Figure 2
Figure 2
Comparison of depression status among HCs, non‐LN SLE, and LN patients. Comparison of HADS‐D score (A) and depression rate (B) among HCs, non‐LN SLE, and LN patients. HADS, Hospital Anxiety and Depression Scale; HCs, health controls; LN, lupus nephritis; SLE, systemic lupus erythematosus disease
See this image and copyright information in PMC

References

    1. Almaani S, Meara A, Rovin BH. Update on lupus nephritis. Clin J Am Soc Nephrol. 2017;12(5):825‐835. - PMC - PubMed
    1. Parikh SV, Almaani S, Brodsky S, Rovin BH. Update on lupus nephritis: core curriculum 2020. Am J Kidney Dis. 2020;76(2):265‐281. - PubMed
    1. Fanouriakis A, Kostopoulou M, Cheema K, et al. 2019 update of the Joint European League Against Rheumatism and European Renal Association‐European Dialysis and Transplant Association (EULAR/ERA‐EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis. 2020;79(6):713‐723. - PubMed
    1. Shin JI, Li H, Park S, et al. Induction and maintenance treatment of lupus nephritis: a comprehensive review of meta‐analyses. J Clin Med . 2022;11(2). - PMC - PubMed
    1. Tamirou F, Houssiau FA. Management of lupus nephritis. J Clin Med . 2021;10(4). - PMC - PubMed